Back to News
Oct 23, 2025 4:20 PM

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion.

The medical technology giant reported adjusted earnings of 75 cents, beating the consensus of 71 cents and the management guidance of 70-72 cents.

Outlook: Boston Scientific forecasts net sales growth of approximately 20% in 2025 on a reported basis and around 15.5% on an organic basis, compared to prior guidance of 18%-19% and 12%-14%, respectively.

The company expects fourth-quarter adjusted earnings of 77 cents to 79 cents, versus a consensus of 76 cents. Sales should range between $5.22 billion and $5.31 billion, versus a consensus ...